SCHEMBL9910035

SCHEMBL9910035

Cc1nc(C2(c3ccc(C(=O)Nc4ccccc4N)cc3)COC2)sc1C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 16/20 0.46
HDAC3 O15379 8/20 0.46
HDAC2 Q92769 7/20 0.46
HDAC4 P56524 4/20 0.46
HDAC7 Q8WUI4 4/20 0.46
HDAC10 Q969S8 4/20 0.46
HDAC11 Q96DB2 4/20 0.46
HDAC8 Q9BY41 4/20 0.46
HDAC6 Q9UBN7 4/20 0.46
HDAC9 Q9UKV0 4/20 0.46
HDAC5 Q9UQL6 4/20 0.46
MAPK1 P28482 1/20 0.45
NCOR2 Q9Y618 1/20 0.44
PTGS1 P23219 1/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
PIK3CA P42336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9910034 0.82 HDAC1 (0.39) HDAC1HDAC3HDAC2HDAC7HDAC8
SCHEMBL197046 0.81 HDAC1 (0.46) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL197448 0.79 HDAC1 (0.44) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL197987 0.76 HDAC2 (0.48) HDAC1HDAC3HDAC2
SCHEMBL199437 0.76 HDAC1 (0.49) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL198446 0.75 HDAC1 (0.48) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL3353718 0.75 HDAC1 (0.52) HDAC1
SCHEMBL3352620 0.74 HDAC1 (0.51) HDAC1
SCHEMBL197554 0.73 HDAC1 (0.48) HDAC1HDAC3HDAC2HDAC4HDAC7
SCHEMBL196952 0.73 HDAC1 (0.44) HDAC1HDAC3HDAC2HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC3 4/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.